Phase 1/2 Duravelo-1 study: Preliminary results of nectin-4–targeting zelenectide pevedotin (BT8009) plus pembrolizumab in previously untreated, cisplatin-ineligible patients with locally advanced or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback